美国国立综合癌症网络止吐指南用于指导临床合理用药的回顾性分析  

Retrospective Analysis of the Clinical Rational Drug Use Refer to NCCN Antiemetic Guideline

作　　者：贺飞[1] 王晓篪 王小兵[1] 樊英[1] 李淑敏[1] 李国辉[1] 

机构地区：[1]中国医学科学院肿瘤医院,北京100021

出　　处：《中国药学杂志》2015年第19期1731-1734,共4页Chinese Pharmaceutical Journal

摘　　要：目的调查妇科肿瘤患者在化疗期间止吐药物的应用情况,为合理用药提供参考。方法回顾性分析182例妇科肿瘤患者病例,并进行描述性统计分析和Logistic回归分析。结果接受单日化疗的患者止吐药物使用的指南符合率为80%,接受多日化疗患者预防用药为95%,其中47%使用了5-HT3受体拮抗剂。结论作为全国最大的肿瘤医院,预防性应用止吐药物的指南符合率高于以往研究结果。妇科肿瘤患者预防性应用止吐药物以5-HT3受体拮抗剂为主,联合应用地塞米松的止吐作用被忽视。OBJECTIVE To investigate the application of antiemetics in patients with gynecological cancers during chemothera- py. METHODS Medical records of 182 patients receiving chemotherapy for gynecological cancer were evaluated and a descriptive a- nalysis was carried out. Logistic regression was performed to determine the predictors of compliance. RESULTS The rate of adher- ence to guideline （CINV） for patients receiving one-day chemotherapy is 80%. prophylactic usage rate in patients receiving nluhi-days chemotherapy is 95%, with a 47% 5-HT3 receptor antagonist. The adherence to NCCN anti-emesis guideline was better in patients having paclitaxel-based chemotherapy than patients having no paclitaxel. CONCLUSION As the biggest cancer hospital in China, antiemetics were commonly given as prevention of CINV in the form of 5-HT3 receptor antagonist, but antiemetic effect of dexametha- soMe was ignored and needed to be emphasized.

关 键 词：妇科肿瘤 止吐药 地塞米松 5-HT3 受体拮抗剂 

分 类 号：R969.3[医药卫生—药理学]